Home » DOV PHARMACEUTICAL GETS NASDAQ LETTER
DOV PHARMACEUTICAL GETS NASDAQ LETTER
Shares of DOV Pharmaceutical Inc. slipped to a fresh 52-week low after the biopharmaceutical company said it received a letter from the Nasdaq that it failed to comply with several listing requirements. The company's market value fell below $50 million
for 10 straight business days, and total assets and total revenue also fell
below $50 million.
Business
Week
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May